Quick Answer
Foghorn Therapeutics Inc. reported Total Assets of $198.10 million for fiscal year 2025.
Foghorn Therapeutics Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $198.10M | -30.2% |
| 2024 | $283.98M | -0.7% |
| 2023 | $285.92M | -29.4% |
| 2022 | $404.88M | -22.1% |
| 2021 | $519.77M | +103.4% |
| 2020 | $255.59M | +1044.0% |
| 2019 | $22.34M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $204.96M | -33.5% | -9.4% |
| June 30, 2025 | $226.24M | -31.1% | -12.5% |
| March 31, 2025 | $258.69M | +1.4% | -8.9% |
| December 31, 2024 | $283.98M | -0.7% | -7.9% |
| September 30, 2024 | $308.37M | -1.6% | -6.2% |
| June 30, 2024 | $328.58M | -3.2% | +28.9% |
| March 31, 2024 | $255.00M | -31.6% | -10.8% |
| December 31, 2023 | $285.92M | -29.4% | -8.8% |
- Foghorn Therapeutics Inc. showed a decrease of -30.2% in Total Assets compared to the prior fiscal year.
- Over the 2019–2025 period, Foghorn Therapeutics Inc.’s total assets has grown by 786.7% (from $22.34 million to $198.10 million).
- The most recent figure is from Foghorn Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: